Pyruvate carboxylase deficiency type C; variable presentation and beneficial effect of triheptanoin
Authors:
Open Access
- 28 December 2023
- journal article
- research article
- Published by Wiley in JIMD Reports
- Vol. 65 (1) , 10-16
Abstract
Pyruvate carboxylase is a mitochondrial enzyme essential for the tricarboxylic acid cycle (TCA), gluconeogenesis and fatty‐acid synthesis. Pyruvate carboxylase deficiency (PCD) mostly presents with life‐limiting encephalopathy (types A/B). A milder type C presentation is rare, with a comparatively favourable prognosis. Therapies remain essentially supportive. Triheptanoin is an odd‐chain triglyceride, with the potential to replenish TCA intermediates (anaplerosis), and its metabolites cross the blood–brain‐barrier. Outcomes of triheptanoin treatment in PCD types A/B have been disappointing, but have not been reported in type C. Here, we present two new patients with PCD type C, and report the response to treatment with triheptanoin in one. Patient 1 (P1) presented with neonatal‐onset lactic acidosis and recurrent symptomatic lactic acidosis following exercise and during illnesses, with frequent hospitalisations. Speech development was delayed. MRI‐brain showed delayed cerebral myelination. Patient 2 (P2) presented with episodic ketoacidosis, hyperlactataemia and hypoglycaemia at 2 years of age, with gross motor delay and mild global volume loss on MRI brain. Treatment with triheptanoin was commenced in P1 at 3 years of age with up‐titration to 35 mL/day (25% of daily energy intake) over 6 months, due to transient diarrhoea. Dietary long‐chain triglycerides were restricted, with fat‐soluble vitamin supplementation. Subsequently, hospitalisations during intercurrent illnesses decreased, post‐exertional hyperlactataemia resolved and exercise tolerance improved. Continued developmental progress was observed, and repeat MRI 18 months after initiation showed improved myelination. Triheptanoin was well‐tolerated and appeared efficacious during 2 years' follow‐up, and has potential to restore energy homeostasis and myelin synthesis in PCD type C.Keywords
Funding Information
- NIHR Great Ormond Street Hospital Biomedical Research Centre
This publication has 18 references indexed in Scilit:
- Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoinEuropean Journal of Pediatrics, 2013
- Pyruvate carboxylase deficiency: Mechanisms, mimics and anaplerosisMolecular Genetics and Metabolism, 2010
- The molecular basis of pyruvate carboxylase deficiency: Mosaicism correlates with prolonged survivalMolecular Genetics and Metabolism, 2008
- A case of pyruvate carboxylase deficiency with atypical clinical and neuroradiological presentationMolecular Genetics and Metabolism, 2006
- Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapyMolecular Genetics and Metabolism, 2005
- Report of a Case and Additional Evidence for the “Mild” PhenotypeClinical Pediatrics, 2001
- Lack of mutations in the biotin-binding region of the pyruvate carboxylase (PC) gene in a family with partial PC deficiencyClinical Biochemistry, 1997
- Prolonged survival in pyruvate carboxylase deficiency: Lack of correlation with enzyme activity in cultured fibroblastsClinical Biochemistry, 1995
- MRI, Clinical, and Biochemical Features of Partial Pyruvate Carboxylase DeficiencyJournal of Child Neurology, 1994
- Pyruvate Carboxylase Deficiency: A Benign Variant with Normal DevelopmentPediatric Research, 1991